Literature DB >> 27303171

Vancomycin-induced Linear IgA Bullous Dermatosis: A Case Report and Review of the Literature.

Min Ju Kang1, Hyung Ok Kim1, Young Min Park1.   

Abstract

Linear IgA bullous dermatosis (LABD) is a rare autoimmune bullous disease that can either occur without any apparent cause or be induced by the administration of certain drugs, the most common of which is vancomycin. We present a case of a 45-year-old woman who was diagnosed with vancomycin-induced LABD by the presence of a characteristic linear band of IgA along the basement membrane zone on direct immunofluorescence microscopy. Our patient showed complete recovery after a 2-week period during which vancomycin administration was discontinued.

Entities:  

Keywords:  Linear IgA bullous dermatosis; Vancomycin

Year:  2008        PMID: 27303171      PMCID: PMC4904051          DOI: 10.5021/ad.2008.20.2.102

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


  11 in total

1.  Drug-induced linear IgA bullous dermatosis probably induced by furosemide.

Authors:  J P Cerottini; C Ricci; D Guggisberg; R G Panizzon
Journal:  J Am Acad Dermatol       Date:  1999-07       Impact factor: 11.527

2.  Acetaminophen-induced linear IgA bullous dermatosis.

Authors:  Oktay Avci; Melda Okmen; Salih Cetiner
Journal:  J Am Acad Dermatol       Date:  2003-02       Impact factor: 11.527

Review 3.  Drug-induced linear IgA bullous dermatosis.

Authors:  Hanae Onodera; Martin C Mihm; Aki Yoshida; Toshihide Akasaka
Journal:  J Dermatol       Date:  2005-09       Impact factor: 4.005

Review 4.  Drug-induced linear IgA disease with antibodies to collagen VII.

Authors:  S H Wakelin; J Allen; S Zhou; F Wojnarowska
Journal:  Br J Dermatol       Date:  1998-02       Impact factor: 9.302

5.  The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2.

Authors:  J J Zone; T B Taylor; L J Meyer; M J Petersen
Journal:  J Invest Dermatol       Date:  1998-03       Impact factor: 8.551

Review 6.  Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis.

Authors:  M A Waldman; D R Black; J P Callen
Journal:  Clin Exp Dermatol       Date:  2004-11       Impact factor: 3.470

7.  Drug-induced linear IgA disease: target antigens are heterogeneous.

Authors:  C Paul; P Wolkenstein; C Prost; F Caux; G Rostoker; M Heller; J Wechsler; J Revuz; J C Roujeau
Journal:  Br J Dermatol       Date:  1997-03       Impact factor: 9.302

8.  Vancomycin-induced linear IgA disease manifesting as bullous erythema multiforme.

Authors:  April Wang Armstrong; Amin Fazeli; Shih Wei Yeh; Bonnie T Mackool; Vincent Liu
Journal:  J Cutan Pathol       Date:  2004-05       Impact factor: 1.587

Review 9.  Early diagnosis is key in vancomycin-induced linear IgA bullous dermatosis and Stevens-Johnson syndrome.

Authors:  Douglas H Jones; Michael Todd; Timothy J Craig
Journal:  J Am Osteopath Assoc       Date:  2004-04

10.  Phenytoin-induced linear IgA dermatosis mimicking toxic epidermal necrolysis.

Authors:  Diana Tran; Steven Kossard; Stephen Shumack
Journal:  Australas J Dermatol       Date:  2003-11       Impact factor: 2.875

View more
  4 in total

1.  A 62-year-old man with new-onset bullae.

Authors:  August J Generoso; Jordana A Goldman; Alan H Wolff
Journal:  Allergy Asthma Proc       Date:  2021-03-01       Impact factor: 2.587

2.  Linear IgA Disease: A Rare Complication of Vancomycin.

Authors:  Maryam Saleem; Hassaan Iftikhar
Journal:  Cureus       Date:  2019-06-06

3.  Vancomycin-Induced Leukocytoclastic Vasculitis and Acute Renal Failure Due to Tubulointerstitial Nephritis.

Authors:  Chandra Shekar Pingili; Emmanuel E Okon
Journal:  Am J Case Rep       Date:  2017-09-25

4.  A Rare Case of Vancomycin-Induced Linear Immunoglobulin A Bullous Dermatosis.

Authors:  Pinky Jha; Kurtis Swanson; Jeremiah Stromich; Basia M Michalski; Edit Olasz
Journal:  Case Rep Dermatol Med       Date:  2017-01-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.